What is OCGN's current stock price?

OCGN (Ocugen, Inc.) is currently trading at $1.34 with a market cap of $453.6M.

What sector is Ocugen, Inc. in?

Ocugen, Inc. (OCGN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is OCGN a good stock to buy?

Analysts have a Buy consensus on OCGN with a price target of $5.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

OCGN Ocugen, Inc.

Healthcare

$1.34-0.74%ClosedMarket Cap: $453.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

73.97

P/S

101.59

EV/EBITDA

-7.01

DCF Value

$-0.19

FCF Yield

-13.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

100.0%

Operating Margin

-1483.9%

Net Margin

-1605.2%

ROE

-127987.5%

ROA

-126.0%

ROIC

-157.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$1.5M	$-19.2M	$—
Q4 null	$-193.0K	$-17.7M	$—
FY null	$4.4M	$-67.8M	$—
Q3 null	$1.8M	$-20.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$5.00

Target (Median)

$5.00

Target Range

$3.50 - $6.00

1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Chardan CapitalBuy

2026-03-25

HC Wainwright & Co.Buy

2026-03-25

Chardan CapitalBuy

2026-01-20

Chardan CapitalBuy

2025-09-19

Chardan CapitalBuy

2025-08-04

Trading Activity

Insider Trades

View All

Zhang Jungedirector

SellThu Apr 02

Zhang Jungedirector

SellThu Apr 02

Zhang Jungedirector

SellThu Apr 02

Johnson-Greene Treerita Essalimaofficer: Chief Financial Officer

SellThu Mar 05

Johnson-Greene Treerita Essalimaofficer: Chief Financial Officer

SellThu Mar 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.31

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Peers